- Record: found
- Abstract: found
- Article: not found
Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.
Mitsuru Sasako
1 ,
Shinichi Sakuramoto ,
Hitoshi Katai ,
Taira Kinoshita ,
Hiroshi Furukawa ,
Toshiharu Yamaguchi ,
Atsushi Nashimoto ,
Masashi Fujii ,
Toshifusa Nakajima ,
Yasuo Ohashi
Nov 20 2011
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The first planned interim analysis (median follow-up, 3 years) of the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer confirmed that the oral fluoropyrimidine derivative S-1 significantly improved overall survival, the primary end point. The results were therefore opened at the recommendation of an independent data and safety monitoring committee. We report 5-year follow-up data on patients enrolled onto the ACTS-GC study.